Immunogenicity and Safety of a Split, Inactivated, Trivalent Influenza Vaccine Administered by Intradermal Route Compared to an Intramuscular Vaccination With Fluzone(R) in Healthy Adults
Trial Snapshot
- Phase
- Phase 2
- Status
- Completed
- Enrollment
- 1,597
- Locations
- 20
Study Overview
Brief Summary
This protocol is to compare the immune response of different influenza vaccines given by two different routes of administration in healthy adults ages 18 to 64 years.
Detailed Description
This is a multi-center, randomized, partially blinded trial to compare the safety and immunogenicity of intramuscularly versus intradermally administered influenza vaccine in healthy 18-64 year old adults. Subjects will have blood drawn immediately prior to and approximately three to four weeks after vaccination. After the completion of the trial, all subjects will be offered influenza vaccine of the 2005-2006 formulation.
Study Design
- Study Type
- Interventional
- Allocation
- Randomized
- Intervention Model
- Parallel
- Primary Purpose
- Prevention
- Masking
- Double
Eligibility Criteria
- Ages
- 18 Years to 64 Years (Adult)
- Sex
- All
- Accepts Healthy Volunteers
- Yes
Inclusion Criteria
- •Subject is healthy, as determined by medical history
- •Over 18 years of age and not yet 65 years old
- •Provides written informed consent
- •Able to attend all scheduled visits and to comply with all trial procedures
- •Women may be menopausal of 1 year or more or sugically sterile. Women of child-bearing potential must agree to be abstinent or to use a licensed form of barrier or hormonal contraception for the entire study period, and have a negative pregnancy test within 24 hours prior to vaccination.
Exclusion Criteria
- •Breast-feeding
- •Receipt of an investigational drug, biologic or device in the 4 weeks preceding the trial vaccination
- •Planned participation in another clinical trial during the present trial period
- •History of Guillain-Barré Syndrome
- •Congenital or acquired immunodeficiency, immunosuppressive therapy such as anti-cancer chemotherapy or radiation therapy within the preceding 6 months, or long-term systemic corticosteroid therapy
- •Hypersensitivity to any of the vaccine components (including eggs or egg products or thimerosol and gelatin) or history of a life-threatening reaction to the trial vaccine or a vaccine containing the same substances
- •Chronic illness that could interfere with trial conduct or completion
- •Blood or blood-derived products received in the past 3 months
- •Has received any inactivated vaccine within 2 weeks or live vaccine within 4 weeks prior to enrollment into this study
- •Vaccination planned within the 4 weeks following the trial vaccination
- •Known current HIV, hepatitis B (HBsAg) or hepatitis C infection or seropositivity
- •Prior vaccination against influenza within the past 6 months
- •Allergy shot in the 7-day period prior to enrollment and must not be scheduled to receive any allergy shots in the 7-day period after enrollment
- •On coumadin or heparin therapy or has known thrombocytopenia or bleeding disorder contraindicating vaccination
- •Subject deprived of freedom by an administrative or court order, or in an emergency setting, or hospitalized without his/her consent
- •Febrile illness temperature >= 37.5°C on Day 0, prior to enrollment and vaccination
- •Any condition, that, in the opinion of the investigator, would pose a health risk to the participant
- •History of alcohol or drug abuse in the last 5 years
- •Planned travel outside the US between vaccination and the second study visit
- •Presence of any active skin disease at the injection site that, in the opinion of the Investigator, would impact vaccine delivery or assessment of vaccination site
Arms & Interventions
Group 3
382 subjects will receive one 3 mcg dose of Fluzone intradermally using the Mantoux technique on Day 0,
Intervention: Trivalent inactivated influenza vaccine (Biological)
Group 4
382 subjects will receive one 15 mcg dose Fluzone vaccine intramuscularly (IM) on Day 0,
Intervention: Trivalent inactivated influenza vaccine (Biological)
Group 1
382 subjects will receive one 6 mcg dose of Trivalent inactivated influenza vaccine (TIV) intradermally (ID) with the BD ID System on Day 0,
Intervention: Trivalent inactivated influenza vaccine (Biological)
Group 2
382 subjects will receive one 9 mcg dose of TIV intradermally (ID) with the BD ID System on Day 0,
Intervention: Trivalent inactivated influenza vaccine (Biological)